The US Food and Drug
Administration has issued a Drug
Safety Communication about rare
cases of underactive thyroid in
infants following the use of contrast
media containing iodine.
In all of the reported cases the
infants were either premature
or had other serious underlying
medical conditions.
“Available evidence leads FDA to
believe that this rare occurrence
is usually temporary and resolves
without treatment or any lasting
effects,” the agency said.
Manufacturers of approved
Iodinated Contrast Media Products
have been required to conduct a
study to investigate the safety issue
further, with no changes to current
prescribing, administration or
monitoring practices recommended.The above article was sent to subscribers in Pharmacy Daily's issue from 18 Nov 15 To see the full newsletter, see the embedded issue below or CLICK HERE to download Pharmacy Daily from 18 Nov 15
BREAST Cancer Network Australia (BCNA) has welcomed a PBAC recommendation to subsidise the breast cancer drug Enhertu (trastuzumab deruxtecan) for HER2-low metastatic breast cancer on the PBS.
PHARMACY Connect (PC2024) has revealed that Olympian Peter Bol will be sharing his journey from adversity to athletic greatness at the conference in Sep in Sydney.
IN WESTERN Australia, Michael’s Chemist Group has started stocking therapeutic Nicotine Vaping Products (NVPs), pursuant to the Federal Government’s new vaping laws (PD 25 Mar).
FREE Pharmacy Daily subscription - never miss another story!
to top
Subscribe to Pharmacy Daily
Pharmacy Daily subscription confirmation
Thank you for signing up! Check your email inbox – you should shortly receive a message with a link which must be clicked to confirm your subscription.
Once you’ve done that you will begin receiving Pharmacy Daily as soon as the next issue is published.